Psoriatic Arthritis Workshop Part 2 OMERACT May 15 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heidje, Christian.

Slides:



Advertisements
Similar presentations
Psoriasis Psoriatic Arthritis Cellulitis
Advertisements

Psoriatic Arthritis Emily Chang Morning Report August 14, 2009 August.
Psoriatic Arthritis: Creating a Model for Cost- Effectiveness Analysis GRAPPA meeting San Antonio, TX October 15, 2004 Supported by Schering Participants:
Wrap-Up and Post Course Self Assessment Dr. Diane Lacaille.
Guidelines Mission Statement “To develop guidelines, based upon the best scientific evidence, for the optimal treatment of patients with psoriatic arthritis.
Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
Identifying Domains of Inquiry in Psoriatic Arthritis Dafna D. Gladman, Professor of Medicine, University of Toronto, Director, Psoriatic Arthritis Program.
First International Psoriatic Arthritis Working Group Meeting: 8/15-17/03 NYC Philip Mease MD.
What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.
Psoriatic Arthritis Maggie Davis Hovda Am report 2/16/2010.
Measuring Signs and Symptoms in Rheumatoid Arthritis David R. Karp, MD, PhD Chief, Rheumatic Diseases UT Southwestern Medical Center David R. Karp, MD,
All About Rheumatoid Arthritis
A complex and severe disabling disease
Spondyloarthritis Khusrow Khidri Spondyloarthritis (or spondyloarthropathy) is the name for a family of inflammatory rheumatic diseases that cause.
GRAPPA Guidelines for PsA: Considerations
GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Philip Mease MD.
Dermatologist’s Role in Managing Psoriatic Arthritis Steven R. Feldman, MD, PhD Professor of Dermatology, Pathology & Public Health Sciences Wake Forest.
Psoriatic arthritis – definition and classification criteria Philip Helliwell Senior Lecturer in Rheumatology University of Leeds.
ANKYLOSING SOPNDYLITIS 僵直性脊椎炎. Definition AS is an inflammatory disorder of unknown etiology that primarily affects the spine, axial skeleton, and large.
ASAS – recent achievements
A history of GRAPPA from inception through the constitution to voting for the committees Philip Helliwell On behalf of the Constitution Committee.
Non-Radiographic Spondyloarthritis Has Greater Work Instability than Other Spondyloarthritis Subtypes in a National Database Sherry Rohekar 1, Robert D.
Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.
PsA: Review of Available Assessment Instruments and Lessons from Trial Results Part II Christian Antoni Friedrich Alexander University Erlangen-Nürnberg.
Case #13 Ellen Marie de los Reyes March 15, 2007.
AM Report 11/24/09 Amy Auerbach  Peak onset between 20 and 30 years  Form of spondyloarthritis (cause inflammation around site of ligament insertion.
CASPAR study Philip Helliwell Will Taylor On behalf of the CASPAR study group.
Group for Research and Assessment in Psoriasis and Psoriatic Artritis PGA/VAS Patient and Physician Perception of disease in Psoriatic Arthritis (3PPsA)
GRAPPA research committee Philip Helliwell. History Steering committee in March 2005 received an application for funds to support a research project No.
QOL/Function/Participation Committee Projects to be done –Validation of current measures: HAQ, SF- 36, DLQI, PsAQOL –Development of MCID – need to validate.
NSAIDs and Radiographic Progression in Ankylosing Spondylitis By Abd El-Samad El-Hewala Professor of Rheumatology and Rehabilitation Faculty of Medicine.
OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Philip Helliwell, Arthur Kavanaugh, Gerry Krueger, Peter.
Psoriatic Arthritis Workshop OMERACT May 14 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian.
INternational Spondyloarthritis Inter- observer Reliability Exercise – the INSPIRE study. Gladman DD, Inman RD, Cook R, Maksymowych W, van der Heijde D,
Assessment of enthesitis in psoriatic arthritis
OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Oliver FitzGerald, Philip Helliwell, Arthur Kavanaugh,
Axial Spondyloarthritis (SpA): Representative Values of Sensitivity and Specificity for Several Tests with the Resulting LRs *LR+ = sensitivity/(1 – specificity);
1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.
Show your Best III By: Brad Moatz MSIV. Presentation 42 y.o. male presents with R foot pain and h/o psoriasis.
GRAPPA Meeting, Oct. 16, 2004 San Antonio, Texas Patient Global Question Alberto Cauli Rheumatology Division University of Cagliari, Italy Director Prof.
Group for Research and Assessment in Psoriasis and Psoriatic Artritis PGA/VAS Patient and Physician Perception of disease in Psoriatic Arthritis (3PPsA)
OMERACT Workshop Outcome Measures in Psoriatic Arthritis
Guideline Development Societal needs have driven guideline development to the forefront: – Aid physician education on new clinical information – Set research.
Outcome Measures in PsA Philip Mease MD Seattle, WA.
GRAPPA Guidelines for PsA: Considerations GRAPPA Guidelines Mission Statement: “To develop guidelines, based upon the best scientific evidence, for the.
OMERACT 8 PsA Module Proposal Submitted by: Dafna Gladman and Philip Mease.
GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.
Psoriatic Arthritis Workshop OMERACT 7 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian Antoni, Philip.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.
Identifying Early Inflammatory Arthritis
Ankylosing Spondylitis
Department of Rheumatology and Connective Tissue Diseases
Enteropathic Arthropathy
Training on the Modular Approach on the assessment and management of psoriatic arthritis (PsA) for dermatology units This PsA Assessment initiative is.
Psoriatic Arthritis.
PASI responder rates (A, B) and total resolution in (C) nail psoriasis, (D) enthesitis and (E) dactylitis in affected patients receiving CZP from Week.
IL-12 and IL-23.
Objective Target population: patients with psoriatic arthritis (PsA)
Effective Management of Psoriatic Arthritis: Tailoring Treatments
Part 1: Disease Activity Measures
Wrap-Up and Post Course Self Assessment
Updated 2016 PsA Core Domain Set.
What on earth is Spondyloarthritis
OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,
Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.
A. A. Percentages of patients with active dactylitis in ≥ 4 digits (fingers or toes) at baseline and Week 12. *p < versus baseline. Data are observed.
Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions
Multivariable model of adjusted
Presentation transcript:

Psoriatic Arthritis Workshop Part 2 OMERACT May 15 th, 2004 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heidje, Christian Antoni, Philip Helliwell, Arthur Kavanaugh, Peter Nash, Christopher Ritchlin, Vibeke Strand, William Taylor

PsA Workshop Breakout Groups GroupRoomFacilitatorsRapporteurs Nautilus Triton Lodge Scripps Marlin Curlew Dolphin Heather Acacia Toyan Pirates Den Merril Alan Silman Maarten Boers George Wells Desiree van der Heijde Doug Veale Peter Nash Phil Conahan Thasia Woodworth Paul Emery Malcolm Smith Peter Brooks Vibeke Strand Jurgen Braun Philip Mease Philip Helliwell Oliver Fitzgerald Artie Kavanaugh Jerry Krueger Christian Antoni Christopher Ritchlin Proton Rahman Will Taylor Neil McHugh Dan Clegg

Results of Delphi Exercise DMARD Active Joint Count Pain Patient global X-ray damage Physical function Acute Phase Reactant Quality of Life Physician global Skin disease Damaged Joint Count Enthesitis Dactylitis Morning stiffness Lumbar mobility Work disability Work limitation Performance Tendonitis Cervical mobility Thoracic mobility MRI/US Sacroiliac signs Fatigue Extra-skeletal Sleep Utility indices

PsA Workshop – Breakout Groups u Instructions: –Each group to rank items to be included in a clinical trial from 1-14 in terms of importance. –If there are others not included which the group feels should be included, add them. –Identify those that are absolutely critical for inclusion in a core set.

Discussion Issues u Several items were not actually domains –Active joint count is used to assess inflammation – replace with JOINT ACTIVITY –Radiology is a method not a domain – replace with STRUCTURAL DAMAGE –Spinal mobility is used to assess axial involvement – replace with AXIAL INVOLVEMENT

Discussion issues (Cont’d) u Three core sets ? –(skin, peripheral, axial disease) –One core set (psoriasis plus arthritis) u Should we look at peripheral joints and axial involvement separately? –Obviously different tools will be used –Should all patients with PsA be assessed for axial involvement? u How many joints to count? –68, 76, 44, 28 (parcimony vs. comprehensiveness)

Discussion issues (Cont’d) u Include Imaging to assess inflammation u Dactylitis and enthesitis combined –Concern about double counting u Meaning of damaged joint count –Deformities, flail joints, ankylosed joints, surgery u Patient global to reflect both skin and joint disease u Should add fatigue and sleep u Tissue assessment

Results of Breakout Groups

Composite Scores

Ranking From Breakout Groups

PsA Workshop – Research Agenda u Optimal joint count u Axial assessment u Enthesitis u Dactylitis u Skin assessment u Imaging (inflammation and damage) u Composite responder indices u Differential tissue response to therapies u Fatigue u Patient Global u Participation